What did we learn out west the past seven days? Orexigen will have to wait at least three more months to learn if it can market its obesity drug. Four companies in our coverage cities inched closer to the public markets. Dendreon CEO John Johnson decided to step down, and Peter Thiel’s Breakout Labs decided to step up with more life sciences funding. Onward to the roundup.
Image: http://www.freedigitalphotos.net
To read the original article: West Coast Biotech Roundup: Dendreon, Venter, Orexigen, & More | Xconomy
